Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma

Dildar Bahar Genc, Cengiz Canpolat, Su Gulsun Berrak

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Purpose: The effectiveness of carboplatin and vincristine chemotherapy in the treatment of low-grade glioma (LGG) is well established. However, carboplatin hypersensitivity reactions (CHR) are a major problem leading to premature cessation of therapy. We aimed to investigate the clinical features and the management strategies in CHR, retrospectively. Method: Fifty LGG patients treated between October 1997 and January 2008 with carboplatin and vincristine were included in the study. Clinical features, management strategies, influence of demographic factors on CHR, and success rate in terms of continuation with carboplatin therapy were evaluated. Results: CHR were observed in 20 (40%) patients and grade I reactions were the most common. The median number of carboplatin doses administered at the first episode of CHR was nine (range 1-41). Only younger age was found to be correlated with the presence of CHR. Nine patients had carboplatin desensitization protocol; eight patients were given various combinations of premedication while three had no modification. Treatment was terminated in five patients due to CHR. Overall success rate was 75%. Conclusions: This is the largest single-center study conducted to investigate the frequency and the management strategies in patients with CHR who were treated with the same chemotherapy protocol for LGG. Premedication and desensitization were the preferred modifications in case of CHR. Overall, the success rate for carboplatin continuation is high in comparison to previous studies. Carboplatin can be continued successfully in many cases with CHR if reactions are managed in a timely fashion.

Original languageEnglish (US)
Pages (from-to)385-393
Number of pages9
JournalSupportive Care in Cancer
Volume20
Issue number2
DOIs
StatePublished - Feb 2012
Externally publishedYes

Fingerprint

Carboplatin
Glioma
Hypersensitivity
Pediatrics
Premedication
Vincristine
Drug Therapy
Therapeutics

Keywords

  • Carboplatin
  • Hypersensitivity
  • Low-grade glioma
  • Management

ASJC Scopus subject areas

  • Oncology

Cite this

Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma. / Genc, Dildar Bahar; Canpolat, Cengiz; Berrak, Su Gulsun.

In: Supportive Care in Cancer, Vol. 20, No. 2, 02.2012, p. 385-393.

Research output: Contribution to journalArticle

Genc, Dildar Bahar ; Canpolat, Cengiz ; Berrak, Su Gulsun. / Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma. In: Supportive Care in Cancer. 2012 ; Vol. 20, No. 2. pp. 385-393.
@article{7f5263018f764ea0b2c4fe18337239fc,
title = "Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma",
abstract = "Purpose: The effectiveness of carboplatin and vincristine chemotherapy in the treatment of low-grade glioma (LGG) is well established. However, carboplatin hypersensitivity reactions (CHR) are a major problem leading to premature cessation of therapy. We aimed to investigate the clinical features and the management strategies in CHR, retrospectively. Method: Fifty LGG patients treated between October 1997 and January 2008 with carboplatin and vincristine were included in the study. Clinical features, management strategies, influence of demographic factors on CHR, and success rate in terms of continuation with carboplatin therapy were evaluated. Results: CHR were observed in 20 (40{\%}) patients and grade I reactions were the most common. The median number of carboplatin doses administered at the first episode of CHR was nine (range 1-41). Only younger age was found to be correlated with the presence of CHR. Nine patients had carboplatin desensitization protocol; eight patients were given various combinations of premedication while three had no modification. Treatment was terminated in five patients due to CHR. Overall success rate was 75{\%}. Conclusions: This is the largest single-center study conducted to investigate the frequency and the management strategies in patients with CHR who were treated with the same chemotherapy protocol for LGG. Premedication and desensitization were the preferred modifications in case of CHR. Overall, the success rate for carboplatin continuation is high in comparison to previous studies. Carboplatin can be continued successfully in many cases with CHR if reactions are managed in a timely fashion.",
keywords = "Carboplatin, Hypersensitivity, Low-grade glioma, Management",
author = "Genc, {Dildar Bahar} and Cengiz Canpolat and Berrak, {Su Gulsun}",
year = "2012",
month = "2",
doi = "10.1007/s00520-011-1123-y",
language = "English (US)",
volume = "20",
pages = "385--393",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma

AU - Genc, Dildar Bahar

AU - Canpolat, Cengiz

AU - Berrak, Su Gulsun

PY - 2012/2

Y1 - 2012/2

N2 - Purpose: The effectiveness of carboplatin and vincristine chemotherapy in the treatment of low-grade glioma (LGG) is well established. However, carboplatin hypersensitivity reactions (CHR) are a major problem leading to premature cessation of therapy. We aimed to investigate the clinical features and the management strategies in CHR, retrospectively. Method: Fifty LGG patients treated between October 1997 and January 2008 with carboplatin and vincristine were included in the study. Clinical features, management strategies, influence of demographic factors on CHR, and success rate in terms of continuation with carboplatin therapy were evaluated. Results: CHR were observed in 20 (40%) patients and grade I reactions were the most common. The median number of carboplatin doses administered at the first episode of CHR was nine (range 1-41). Only younger age was found to be correlated with the presence of CHR. Nine patients had carboplatin desensitization protocol; eight patients were given various combinations of premedication while three had no modification. Treatment was terminated in five patients due to CHR. Overall success rate was 75%. Conclusions: This is the largest single-center study conducted to investigate the frequency and the management strategies in patients with CHR who were treated with the same chemotherapy protocol for LGG. Premedication and desensitization were the preferred modifications in case of CHR. Overall, the success rate for carboplatin continuation is high in comparison to previous studies. Carboplatin can be continued successfully in many cases with CHR if reactions are managed in a timely fashion.

AB - Purpose: The effectiveness of carboplatin and vincristine chemotherapy in the treatment of low-grade glioma (LGG) is well established. However, carboplatin hypersensitivity reactions (CHR) are a major problem leading to premature cessation of therapy. We aimed to investigate the clinical features and the management strategies in CHR, retrospectively. Method: Fifty LGG patients treated between October 1997 and January 2008 with carboplatin and vincristine were included in the study. Clinical features, management strategies, influence of demographic factors on CHR, and success rate in terms of continuation with carboplatin therapy were evaluated. Results: CHR were observed in 20 (40%) patients and grade I reactions were the most common. The median number of carboplatin doses administered at the first episode of CHR was nine (range 1-41). Only younger age was found to be correlated with the presence of CHR. Nine patients had carboplatin desensitization protocol; eight patients were given various combinations of premedication while three had no modification. Treatment was terminated in five patients due to CHR. Overall success rate was 75%. Conclusions: This is the largest single-center study conducted to investigate the frequency and the management strategies in patients with CHR who were treated with the same chemotherapy protocol for LGG. Premedication and desensitization were the preferred modifications in case of CHR. Overall, the success rate for carboplatin continuation is high in comparison to previous studies. Carboplatin can be continued successfully in many cases with CHR if reactions are managed in a timely fashion.

KW - Carboplatin

KW - Hypersensitivity

KW - Low-grade glioma

KW - Management

UR - http://www.scopus.com/inward/record.url?scp=84855206094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855206094&partnerID=8YFLogxK

U2 - 10.1007/s00520-011-1123-y

DO - 10.1007/s00520-011-1123-y

M3 - Article

VL - 20

SP - 385

EP - 393

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 2

ER -